Atgam Market Forecast Signals New Revenue Opportunities Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Atgam Market Forecast Highlighting Growth From $ Billion To $ Billion
The expansion observed during the historical period was driven by its demonstrated clinical efficacy in suppressing T cells, a well-established application in the treatment of aplastic anemia, increased adoption within transplant medicine, the scarcity of alternative therapeutic options, and the reliance on hospital-based immunosuppression regimens.
The expansion observed during the forecast timeframe is driven by a rise in the number of transplant surgeries performed, a heightened need for precision-based immunosuppression, the broadening of specialized hematology care, enhancements in supportive care systems, and ongoing incorporation into clinical protocols. Key developments shaping this period encompass sustained application in managing aplastic anemia, an increasing function in controlling transplant rejection, the growth of biologic immunosuppressive treatments, better results achieved in blood-related conditions, and more frequent utilization at dedicated transplantation facilities.
Download A Free Sample Report For Comprehensive Market Insights:
Atgam Market Expansion Supported By Key Demand Factors
The anticipated growth of the atgam market is largely fueled by the increasing frequency of organ transplant procedures. This surgical process involves replacing a patient’s diseased or malfunctioning organ with a healthy one sourced from a donor. Several factors contribute to the uptick in transplant numbers, including the prevalence of chronic illnesses, an aging demographic, and heightened levels of research activity and financial backing. Atgam, also referred to as anti-thymocyte globulin, plays a crucial role in these surgeries by specifically targeting and eliminating T-cells, which helps lower immune responses and stave off acute rejection. It is frequently employed alongside other immunosuppressive medications to improve graft survival and patient outcomes. To illustrate, the Organ Procurement and Transplantation Network, a U.S.-based nonprofit dedicated to scientific and educational endeavors, reported in January 2025 that the country saw 48,149 organ transplants in 2024. This number crossed the 48,000 mark and represented a 3.3 percent rise from the previous year, with 41,119 coming from deceased donors and 7,030 from living ones. As a result, the upward trend in organ transplantation rates is a key force driving the expansion of the atgam market.
The atgam market is increasingly propelled by the expanding geriatric population. This group consists of individuals aged 65 or older, often termed elderly, who typically need specialized healthcare and support services. Progress in healthcare and medical technologies has significantly advanced treatment options, care delivery, and preventive strategies, leading to a notable extension of life expectancy and consequently a larger elderly demographic. Atgam helps avert organ rejection and manage autoimmune conditions in older adults, who face a heightened risk of immune-related health issues. By adjusting the immune system, it supports better transplant results and enhances the overall well-being for senior patients. For example, in October 2024, the World Health Organization, an intergovernmental entity based in Switzerland, estimated that by 2030, approximately one in six individuals globally will be 60 years old or older. The worldwide count of people aged 60 and above is predicted to expand significantly, reaching 1.4 billion by 2030. By 2050, this segment is expected to hit 2.1 billion, roughly doubling present numbers. Furthermore, the population aged 80 and over is anticipated to triple within the same timeframe, rising to around 426 million by 2050. Thus, the continuous growth of the elderly population is a major factor driving the atgam market forward.
Atgam Market Segment Outlook: Which Categories Are Expanding The Fastest?
The atgam market covered in this report is segmented –
1) By Clinical Indication: Renal Transplant Rejection, Aplastic Anemia
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
3) By End-User: Adult Patients, Geriatric Patients
Atgam Market Growth Trends Influencing Competitive Dynamics
Major players in the atgam market are prioritizing label updates as a key strategy for ensuring regulatory compliance and enhancing product transparency. This process entails submitting updated clinical, safety, or pharmacokinetic information to regulators so that product labels stay current and reflect the latest scientific evidence. For example, in February 2023, Pfizer Inc., a U.S.-based global pharmaceutical firm, filed a Prior Approval Supplement (PAS) aimed at revising the pharmacokinetic (PK) data on the label for ATGAM (anti-thymocyte globulin [equine]) sterile solution. This product is indicated for the treatment of renal allograft rejection as well as moderate to severe aplastic anemia. The submission integrates PK data derived from a study involving Japanese adults with aplastic anemia, which will be incorporated into the Ethnicity subsection of the Pharmacokinetics label. The proposed changes have been largely endorsed, though certain adjustments have been requested.
Atgam Market Key Companies And Competitive Benchmarking
Major companies operating in the atgam market are Pfizer Inc.
Access The Complete Atgam Market Report:
Atgam Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the atgam market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atgam market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
